COPENHAGEN (Reuters) -Novo Nordisk’s shares fell around 5% in early trade on Friday after U.S. President Donald Trump said on Thursday that the price of the Danish drugmaker’s best-selling weight-loss drug would be lowered.
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
Comments